Dianthus Therapeutics, Inc. (DNTH) NASDAQ
84.97
+3.4(+4.17%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
84.97
+3.4(+4.17%)
Currency In USD
Address
7 Times Square
New York City, NY 10036
United States of America (the)
Phone
929-999-4055
Website
Sector
Healthcare
Industry
Biotechnology
Employees
78
First IPO Date
June 21, 2018
| Name | Title | Pay | Year Born |
| Marino Garcia | President, Chief Executive Officer & Director | 1.16M | 1966 |
| Ryan Savitz | Executive VP, CFO, Chief Business Officer & Treasurer | 786,096 | 1989 |
| Simrat Randhawa | Executive Vice President and Head of R&D | 932,680 | 1970 |
| Adam Veness | Senior Vice President, General Counsel & Secretary | 0 | 1986 |
| Debra Segal | Head of Regulatory Affairs | 0 | N/A |
| Jennifer Davis Ruff | Vice President and Head of Investor Relations & Corporate Affairs. | 0 | N/A |
| Rashieda Gluck | Head of Clinical Development Operations | 0 | N/A |
| Edward G. Carr | Senior VP & Chief Accounting Officer | 0 | 1969 |
| Judson Taylor | Senior Vice President & Head of Technical Operations | 0 | N/A |
| Kristina Maximenko | Chief People Officer | 0 | N/A |
| Scott Nogi | Head of Business Operations | 0 | N/A |
| Polly Hanff | Head of Quality | 0 | N/A |
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.